The FDA has granted Israeli company Atox Bio’s tissue infection treatment AB103 fast track status. AB103 is designed to treat Necrotizing Soft Tissue Infections. The company will begin testing on 40 patients, suffering from the condition, which causes severe infection to the skin. There is currently no approved treatment for the condition.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

People With Autism Experience Higher Intensity Pain
January 30, 2023

Israeli Innovation At New Bahraini Hospital
January 30, 2023

US Car Giant Signs Up For AI Vehicle Inspections
January 29, 2023

Considerate Partners Are Less Likely To Cheat
January 29, 2023
Facebook comments